Gemifioxacin (CAS 175463-14-6) Suppliers and Product Information

Gemifioxacin is a fluoronaphthyridone derivative with antimicrobial activity. It is effective against both Gram-positive and Gram-negative bacteria, including methicillin-resistant staphylococci. The drug is used for treating bacterial infections, particularly community-acquired pneumonia and acute exacerbations of chronic bronchitis in ***s.

Gemifioxacin has a broad antibacterial spectrum, showing high potency against Streptococcus pneumoniae and good activity against various respiratory tract pathogens. It is less likely to select for quinolone-resistant Str. pneumoniae strains compared to other quinolones.

The drug is formulated as the mesylate salt and is administered orally. It has good bioavailability and achieves excellent concentrations in serum and various tissues. The elimination half-life ranges from 6 to 9 hours, with 26-40% of administered doses eliminated in urine.

Frequently Asked Questions about Gemifioxacin

Q: What are the main uses of Gemifioxacin?

A: Gemifioxacin is primarily used for treating community-acquired pneumonia and acute exacerbations of chronic bronchitis in ***s.

Q: What is the mechanism of action of Gemifioxacin?

A: Gemifioxacin inhibits both DNA gyrase and DNA topoisomerase IV enzyme systems in bacteria, interfering with their ability to replicate and repair DNA.

Q: What are the common side effects of Gemifioxacin?

A: The most commonly reported side effects are diarrhea (3.6%), rash (2.8%), and nausea (2.7%). The overall incidence of drug-related rash is 2.8%, which is usually mild and self-limiting.

Q: How is Gemifioxacin administered?

A: Gemifioxacin is administered orally, typically as a 320 mg tablet. The absolute bioavailability of the oral tablet is around 71%.

Q: Does Gemifioxacin require dosage adjustment in patients with liver or kidney problems?

A: No dosage adjustment is recommended for patients with mild, moderate, or severe hepatic impairment. However, clearance is reduced in patients with renal insufficiency, leading to an increase in plasma concentration. Dosage adjustment may be necessary for patients with severe renal impairment.